Using temozolomide as a first new alkalating agent approved for treatment of malignant gliomas describe its mechanism of action, clinical benefits and major site effects. Compare to other compounds with similar mechanism of action.
2. Present the comparison of clinical benefits of the use of antineoplastic drugs. What criteria are used for selection and for monitoring of most commonly used antineoplastic drugs?
3. Briefly present the mechanism of action of inhibitors of intracellular signaling used for antineoplastic therapy?
4. Give your insights regarding present and future of biological therapies for cancer treatment.
Malignant gliomas are considered to be a class of brain tumor, accounts for around 45% of tumors in the central nervous system. There are mainly three different types of malignant gliomas, namely astrocytomas, ependymomas, and oligodendrogliomas. In malignant gliomas, the solid tumors generally grow into the brain tissue and make it really difficult to be surgically removed.
The malignant cells proliferate and eventually infiltrate into the normal brain tissue. The symptoms generally include loss of memory, persistent headache, seizure, loss of cognitive behavior, language problems, loss of movements and personality changes. Astrocytomas involve a type of brain cells, called astrocytes, accounts for more than 50% of the solid brain tumors. On the contrary, ependymomas start in ependymal cells, less universal in nature, accounts for 2-3% of the brain tumors.
The post Using temozolomide as a first new alkalating agent approved for treatment of malignant gliomas describe its mechanism of action, clinical benefits and major site effects. Compare to other compounds with similar mechanism of action. appeared first on Dissertation Help Service.